🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.

RecruitingNAAges 18 Years - anyAllCentre Georges Francois Leclerc
NCT06550687 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene study offers the opportunity to study patient-physician communication, to assess patient preferences with regard to different information modalities concerning theranostic exome analysis, and to reflect on information modalities to ensure optimal patient comprehension of the information provided. The qualitative cross-sectional study includes a dual observational and interventional component involving cancer patients. The patients will come from the EXOMA 2 active file at Dijon University Hospital and the CGFL.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient identified for inclusion in the EXOMA 2 study (exome analysis request) * Available to receive different types of information * Fluent in French * No prior oncogenetic consultation * Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study * Authorizing audio recording of consultations and interviews Exclusion Criteria: * Patient who refused to participate in the EXOMA2 study (for phase 3 patients only) * Has a psychiatric, cognitive or neurological disorder that makes participation impossible * Working in the field of genetics
💊

What it tests

  • Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis
📍

Where

2 sites
Centre Georges-François Leclerc
Dijon, France
CHU François Mitterand
Dijon, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy